NEW YORK, Dec. 17, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) securities between August 8, 2023 and November 28, 2023, inclusive (the "Class Period"). Click Here to Join the Action.
If you purchased Eagle securities during the Class Period and would like to discuss our investigation, your rights, or your interests please click here. You may also contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571.
If you are a member of the proposed Class, you may move the court no later than February 10, 2024 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff ...